肾康注射液治疗慢性肾功能衰竭CKD3~4期的临床疗效观察  

Clinical Observation of Shenkang Injection in Treating CKD3-4 Chronic Renal Failure

作　　者：李爽 LI Shuang(Yingkou Economic and Technological Development Zone Central Hospital(the Sixth People's Hospital of Yingkou city),Yingkou 115007,China)

机构地区：[1]营口经济技术开发区中心医院(营口市第六人民医院),辽宁营口115007

出　　处：《中国医药指南》2020年第20期178-179,共2页Guide of China Medicine

摘　　要：目的观察肾康注射液治疗慢性肾功能衰竭CKD3~4期的临床疗效。方法从本院2016年1月至2018年8月收治的慢性肾功能衰竭CKD3~4期患者中,抽取86例,采用数字单双原则将43例单号患者分为对照组,将43例双号患者分为观察组。对照组实施常规对症治疗,观察组在常规治疗基础上增加给予肾康注射液进行治疗,观察两组患者肾功能各项指标水平、不良反应、治疗效果以及两组患者治疗前后生活质量评分。结果①观察组患者肾功能血肌酐(Scr)、尿素氮(BUN)、24 h尿蛋白定量水平均显著低于对照组,两组间差异有统计学意义(P<0.05);②观察组和对照组不良反应发生率均较低,且两组间差异无统计学意义(P>0.05);③观察组患者临床治疗效果总有效率显著高于对照组,两组间差异有统计学意义(P<0.05);⑷治疗前观察组和对照组生活质量评分无显著差异,治疗后观察组患者心理状态、社会功能以及生理职能等评分均显著低于对照组(P<0.05)。结论在慢性肾功能衰竭CKD3~4期患者临床治疗中采用肾康注射液进行治疗能够有效改善患者肾功能Scr、BUN、24 h尿蛋白定量水平,促进患者肾功能恢复,提高临床治疗效果和生活质量评分,且安全性较高,未见因应用肾康注射液有关的不良反应情况发生。Objective To observe the clinical effect of Shenkang injection on CKD3-4 chronic renal failure.Methods From January 2016 to August 2018,86 patients with CKD3-4 chronic renal failure were selected.43 patients with CKD3-4 were divided into control group and observation group according to the principle of digital singleton and double.The control group was treated with routine symptomatic treatment,while the observation group was treated with Shenkang injection on the basis of routine treatment.The indexes of renal function,adverse reactions,therapeutic effects and quality of life scores of the two groups were observed before and after treatment.Results(1)The levels of serum creatinine(Scr),urea nitrogen(BUN)and 24-hour urinary protein in the observation group were significantly lower than those in the control group,and there was significant difference between the two groups(P<0.05);(2)The incidence of adverse reactions in the observation group and the control group was lower,and there was no significant difference between the two groups(P>0.05).(3)The total effective rate of clinical treatment in the observation group was significantly higher than that in the control group,and there was a significant difference between the two groups(P<0.05).(4)There was no significant difference in the scores of quality of life between the observation group and the control group before treatment.After treatment,the scores of psychological state,social function and physiological function of the observation group were significantly lower than tho se of the control group(P<0.05).Conclu sion Shenkang inj ection can effectively improve the Scr,BUN and 24-hour urinary protein levels in patients with CKD3-4 chronic renal failure,promote the recovery of renal function and improve the clinical therapeutic effect and quality of life score.It is safe and has no adverse reactions related to the application of Shenkang inj ection.

关 键 词：肾康注射液 慢性肾功能衰竭 肾功能 不良反应 治疗效果 

分 类 号：R692.5[医药卫生—泌尿科学]